Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Sci Rep · 2019 · PMC6441028 · PMID 30926892

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

Comparison between pioglitazone dosage showed that 30 mg fixed-dose was similarly efficacious as the comparators (WMD: −0.01, 95% CI: −0.29 to 0.28, p = 0.96), whereas 45 mg fixed-dose showed a trend towards greater HbA1c reduction compared with other AD drugs (WMD: −0.48, 95% CI: −1.04 to 0.07, p = 0.09).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Apart from the aforementioned adverse events, analysis of other reported adverse events during pioglitazone treatment did not reach statistical significance due to insufficient included studies and therefore, these results were not able to evaluate the safety profile of pioglitazone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.